{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2009"],"condition":["Metastatic Colorectal Cancer","Colorectal carcinoma","Behandlingsresistente patienter med metastaserende colorectal cancer og KRAS mutationer","Colorectal Neoplasms"],"disease":["Colorectal Carcinoma","Metastatic Colorectal Cancer","Colorectal Neoplasms","Behandlingsresistente Patienter Med Metastaserende Colorectal Cancer Og Kras Mutationer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2066730"],"location":["Denmark"],"study_start_month":["3"],"keyword":["Irinotecan","KRAS mutation","Irinotecan \"Mayne\"","MTOR Inhibitors","Sirolimus","Temsirolimus"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations","description":"The purpose of this study is to investigate the safety and efficacy of temsirolimus as a single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant patients with KRAS mutated colorectal cancer.","dates":{"creation":"2009-03-15"},"accession":"2066730","cross_references":{"ClinicalTrials___gov":["NCT00827684"],"EU Clinical Trials Register":["2008-007665-22"]}}